- Latest available (Revised) - English
- Latest available (Revised) - Welsh
- Point in Time (22/04/2011)
- Original (As made) - English
- Original (As made) - Welsh
Version Superseded: 12/04/2013
Point in time view as at 22/04/2011.
There are currently no known outstanding effects for the The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004, SCHEDULE 2.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 3
Commencement Information
I1Sch. 2 in force at 1.4.2004, see reg. 1(1)
Column 1 | Column 2 | Column 3 |
---|---|---|
Drugs | Patient | Condition |
In this Schedule— [F1“at-risk” means an adult or child patient or a patient aged 13 years or older who— (a) has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease); (b) has significant cardiovascular disease, excluding an adult or child patient who has hypertension only; (c) has chronic renal disease; (d) is immunocompromised; (e) has diabetes mellitus; or (f) is aged 65 years or over;] [F1“child” means any person under the age of 16 years;] “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992(4) as adjusted by the Protocol signed at Brussels on 17th March 1993(5) and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994(6); “EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. [F2“Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza;] [F1“patient” has the same meaning as in the National Health Services (General Medical Services Contracts) (Wales) Regulations 2004;] [F1“residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care.] | ||
Clobazam | Any patient | Treatment of epilepsy |
Cyanocobalamin Tablets | A patient who is a vegan or who has a proven vitamin B12 deficiency of dietary origin | Treatment or prevention of vitamin B12 deficiency |
Locabiotal Aerosol | Any patient | Treatment of infections and inflammation of the oropharynx |
Niferex Elixir 30ml Paediatric Dropper Bottle | Infants born prematurely | Prophylaxis and treatment of iron deficiency |
Nizoral Cream | Any patient | Treatment of seborrhoeic dermatitis and pityriasis versicolor |
[F3Oseltamivir (Tamiflu) | (1) At-risk adult and child patients where — (a)It has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b)the patient has an influenza-like illness; and (c)the patient can start therapy within 48 hours of the onset of symptoms. | Treatment of influenza |
(2) At-risk patients who are aged 13 years and older where — (a)it has been determined in accordance with a community-based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides; (b)the patient has been exposed to an influenza-like illness as a result of being in close contact with someone with whom the patient lives who is, or has been, suffering from an influenza-like illness; (c)the patient is not effectively protected by vaccination against influenza because the patient — (i)has not been vaccinated because vaccination is contra-indicated; (ii)has not been vaccinated since the previous vaccination season; (iii)has been vaccinated but the vaccination has yet to take effect; or (iv)the patient has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present; (d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and (e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness. | Prophylaxis of infinfluenza] | |
[F4(3) Adult and child patients where—
| Treatment and prophylaxis of influenza] | |
The following drugs for the treatment of erectile dysfunction— Alprostadil (Caverject), (MUSE), (Viridal) Apomorphine Hydrochloride (Uprima) Moxisylyte Hydrochloride (Erecnos) Sildenafil (Viagra) Tadalafil (Cialis) Thymoxamine Hydrochloride (Erecnos) Vardenafil (Levitra) | (a)a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland) Act 1978(1) or the Health and Personal Social Services (Northern Ireland) Order 1972(2) for this condition with any of the following drugs—
(b)man who is a national of an EEA State who is entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68(3) as extended by the EEA Agreement or by virtue of any other enforceable [F5EU] right who has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for this condition with any of the drugs listed in sub-paragraph (a); or (c)a man who is not a national of an EEA State but who is the member of the family of such a national who has an enforceable [F5EU] right to be treated no less favourably than the national in the provision of medical treatment and has erectile dysfunction and was being treated for that condition on 14th September 1998 with any of the drugs listed in sub-paragraph (a); or (d)a man who is suffering from any of the following—
(e)a man who is receiving treatment for renal failure by dialysis; or (f)a man who has had the following surgery —
| Treatment of erectile dysfunction |
[F3Zanamivir (Relenza) | [F6(1)] At-risk adult patients where— (a) it has been determined in accordance with a community based virological surveillance scheme that influenza A and influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b) the patient has an influenza-like illness; and (c) the patient can start therapy within 48 hours of the onset of the symptoms. | Treatment of influenza] |
[F7(2) Adult and child patients where—
| Treatment and prophylaxis of influenza] |
Textual Amendments
F1Words in Sch. 2 inserted (4.4.2005) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2005 (S.I. 2005/366), regs. 1(1), 2(2)(b)
F2Words in Sch. 2 inserted (10.7.2009) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc) (Wales) (Amendment) Regulations 2009 (S.I. 2009/1838), regs. 1(1), 2(2)(b)
F3Words in Sch. 2 inserted (4.4.2005) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2005 (S.I. 2005/366), regs. 1(1), 2(2)(a)
F4Words in Sch. 2 inserted (10.7.2009) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc) (Wales) (Amendment) Regulations 2009 (S.I. 2009/1838), regs. 1(1), 2(2)(a)
F5Words in Instrument substituted (22.4.2011) by The Treaty of Lisbon (Changes in Terminology) Order 2011 (S.I. 2011/1043), arts. 2, 3-6, 8-10
O.J. No. L257, 19.10.68, p.22.
Cm. 2073 and O.J. No. L1, 3.1.1944, p.3.
Cm. 2183 and O.J.No. L1, 3.1.1994, p.572.
O.J. No. L160, 28.6. 1996, p.1.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: